Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 11,393 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Wounds and Injuries, Wound Infection, Facial Bones Fracture, Soft Tissue Injuries, Skull Fractures, Surgical Wound, Surgical Wound Infection, Wound Healing, Disturbance of Wound Healing, Wound; Head, Multiple, Wound; Head, Scalp, Wound; Head, Wound Complication, Wound Dehiscence, Wound of Skin, Wound Open, Wounds, Penetrating, Wounds, Nonpenetrating, Wounds
Interventions: Not listed
Lead sponsor: Dufresne, Craig, MD, PC; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Healthy Participants
Interventions: Lu AG06474, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Language Development
Interventions: TMW ECE Curriculum; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gliomas
Interventions: Ulixertinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Resuscitation, Trauma Patients
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Arthritis, Reactive, Arthritis, Rheumatoid, Synovitis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions: PRI-724; Drug
Lead sponsor: Prism Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more

Conditions: Pregnancy
Interventions: Hydroxyprogesterone caproate 250 mg/ml; Drug
Lead sponsor: Lumara Health, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Lake Worth, Florida • Idaho Falls, Idaho • Chicago, Illinois + 3 more

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Dasatinib, Cisplatin, Radiation Therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbus, Ohio

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: becatecarin, oxaliplatin, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy Participants
Interventions: AZD6234, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 142 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Smallpox
Interventions: Live vaccinia virus vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 32 Years to 70 Years
Enrollment: 927 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 7
States / cities: Oakland, California • Stanford, California • Torrance, California + 4 more

Conditions: Breast Cancer
Interventions: Letrozole, Palbociclib, Goserelin, Oncotype DX Breast Recurrence Score; Drug · Diagnostic Test
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Fountain Valley, California • Laguna Hills, California • Long Beach, California + 5 more

Conditions: Healthy Participants
Interventions: PF-07293893, Placebo, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Healthy Participants, Dyslipidemia
Interventions: AZD4954, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Year and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions: M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine; Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: VC-01™ Combination Product; Combination Product
Lead sponsor: ViaCyte; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Hepatitis C Virus Infection
Interventions: Not listed
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Tauopathies
Interventions: BMS-986168, BMS-986168 Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Cypress, California • Dallas, Texas

Conditions: Incident Type 2 Diabetes, Incident Obesity
Interventions: No intervention in an observational study; Other
Lead sponsor: Des Moines University; Other
Eligibility: 40 Years to 60 Years · Male only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Neoplasms, Tumor
Interventions: IMC-TR1; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas • San Antonio, Texas

Conditions: Allergy
Interventions: Intradermal cat allergen challenge; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Cold-Pressor Task (CPT), Control CPT, fMRI; Behavioral · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 64 Years
Enrollment: 397 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds

A Study Investigating Lu AG06474 in Healthy Young Participants

Thirty Million Words-Early Childhood Educator (TMW-ECE)

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

Early Aggressive Correction of Severe Acidosis With Tris-hydroxymethylaminomethane (THAM)

Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood

A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC

Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Identifying Genetic Causes of IC/BPS

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity

A Study of IMC-TR1 in Participants With Advanced Solid Tumors

LYmph Node eXamination in Cat Allergen Immunotherapy

Neural Mechanisms of Cost and Benefit Integration During Decision-Making, Aim 2: Acute & Lifetime Stress